| Health / Medical Topics |
Glioblastoma Cancer Vaccine ERC1671
A cancer vaccine composed of a combination of autologous glioblastoma (GBM) tumor cells, allogeneic GBM tumor cells, generated from three different GBM donor cancer patients, and the lysates of all of these cells, with potential antineoplastic activity. Upon intradermal administration of GBM cancer vaccine ERC1671, the mixture of the autologous and allogeneic cells and lysates stimulates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against GBM-associated antigens, which leads to the destruction of glioblastoma cells. (NCI Thesaurus)
YOU MAY ALSO LIKE
Classification of glioblastoma into molecular subtypes as defined by gene expression profiling.
A fast-growing type of central nervous system tumor that forms from glial (supportive) tissue of the brain and spinal cord and has…
A long-acting, third-generation sulfonylurea with hypoglycemic activity. Compared to other generations of sulfonylurea compounds, glimepiride is very potent and has a longer…
A fluoro-containing sulfadiazine derivative with hypoglycemic activity. Although not technically a sulfonylurea compound, gliflumide targets the sulfonylurea receptor and exerts a similar…
A second-generation, sulfonamide urea derivative with antihyperglycemic activity. Glidazamide's hypoglycemic effect is inferior to that of glicaramide.
An inactive ingredient of the solid pharmaceutical dosage form added to cement the active and inert components of tablets together to maintain…
